PTEN and metastatic prostate carcinoma: In general, the gene expression did not show strong overall correlations with each other, biopsy site, or the most common genomic alterations in metastatic prostate cancer such as AR mutations/amplifications, MYC amplification, or RB1/TP53/PTEN loss (Fig. 3).